https://www.nature.com/articles/d41586-023-00648-3
" In the past four years, three of these trials were halted early because the benefits were so clear. In the CREDENCE study4, for instance, canagliflozin reduced the combined risk of end-stage renal disease or death from cardiovascular or kidney-related events by 30%."
"“It’s an exciting time for nephrology,” says Adeera Levin, a nephrologist at the University of British Columbia in Vancouver, Canada, and executive director of BC Renal, an organization that oversees kidney services in British Columbia."
ACTION3
https://www.nature.com/articles/d41586-023-00648-3" In the past...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
0.025(7.46%) |
Mkt cap ! $197.8M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 36.3¢ | 33.5¢ | $3.801M | 10.73M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 378856 | 6 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
36.0¢ |
Change
0.025 ( 7.33 %) |
||||
| Open | High | Low | Volume | ||
| 33.5¢ | 36.5¢ | 33.5¢ | 5557634 | ||
| Last updated 15.58pm 03/05/2024 ? | |||||
| DXB (ASX) Chart |